Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
| العنوان: | Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes |
|---|---|
| المؤلفون: | Chan Uk Heo, Chang-Ik Choi |
| المصدر: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 8, Iss 3, p 393 (2019) |
| بيانات النشر: | MDPI AG, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, precision medicine, lcsh:Medicine, 030209 endocrinology & metabolism, Review, Type 2 diabetes, Hypoglycemia, 03 medical and health sciences, 0302 clinical medicine, DPP-4 inhibitors, Diabetes mellitus, medicine, Intensive care medicine, pharmacogenetics, 030304 developmental biology, GLP-1 receptor agonists, 0303 health sciences, business.industry, lcsh:R, personalized medicine, General Medicine, Precision medicine, medicine.disease, Metformin, second-line antidiabetic medications, Pharmacogenomics, type 2 diabetes, Personalized medicine, business, SGLT2 inhibitors, Pharmacogenetics, medicine.drug |
| الوصف: | Precision medicine is a scientific and medical practice for personalized therapy based on patients’ individual genetic, environmental, and lifestyle characteristics. Pharmacogenetics and pharmacogenomics are also rapidly developing and expanding as a key element of precision medicine, in which the association between individual genetic variabilities and drug disposition and therapeutic responses are investigated. Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia mainly associated with insulin resistance, with the risk of clinically important cardiovascular, neurological, and renal complications. The latest consensus report from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) on the management of T2D recommends preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and some dipeptidyl peptidase-4 (DPP-4) inhibitors after initial metformin monotherapy for diabetic patients with established atherosclerotic cardiovascular or chronic kidney disease, and with risk of hypoglycemia or body weight-related problems. In this review article, we summarized current progress on pharmacogenetics of newer second-line antidiabetic medications in clinical practices and discussed their therapeutic implications for precision medicine in T2D management. Several biomarkers associated with drug responses have been identified from extensive clinical pharmacogenetic studies, and functional variations in these genes have been shown to significantly affect drug-related glycemic control, adverse reactions, and risk of diabetic complications. More comprehensive pharmacogenetic research in various clinical settings will clarify the therapeutic implications of these genes, which may be useful tools for precision medicine in the treatment and prevention of T2D and its complications. |
| تدمد: | 2077-0383 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46b5676e57994031b104022e0d54f42Test https://doi.org/10.3390/jcm8030393Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f46b5676e57994031b104022e0d54f42 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20770383 |
|---|